For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
De novo Renal Transplantation after Kaposi Sarcoma: Favorable Outcome in a Patient Receiving Sirolimus and Mycophenolate-Based ImmunosuppressionFriedersdorff F.a · Giessing M.d · Roller C.a · Baumunk D.a · Deger S.a · Budde K.b · Liefeldt L.b · Hartmann V.c · Fuller T.F.a
Departments of aUrology, bNephrology, and cDermatology, Charité Campus Mitte, Universitätsmedizin Berlin, Berlin, and dDepartment of Urology, Heinrich-Heine Universität, Düsseldorf, Germany Corresponding Author
Charité – Universitätsmedizin Berlin
Department of Urology, Campus Mitte
Charitéplatz 1, DE–10117 Berlin (Germany)
Tel. +49 30 450 615 219, Fax +49 30 450 515 910, E-Mail email@example.com
Immunosuppressive treatment increases the risk of infection and malignancy in organ transplant recipients. We report on a 42-year-old male renal transplant recipient who lost his first graft after reduction of immunosuppressive treatment due to Kaposi sarcoma and who successfully underwent a second renal transplant 10 years later. The patient’s current treatment consists of low-dose prednisone, and the two antiproliferative immunosuppressants mycophenolate mofetil and rapamycin. 4.5 years after his second transplant, the serum creatinine is 1 mg/dl and the patient has no signs of recurrent disease.
© 2010 S. Karger AG, Basel